

Yijuang Chern

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5192331/yijuang-chern-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

3,822
citations

38
h-index

58
g-index

101
ext. papers

4,291
ext. citations

6.5
avg, IF

5.21
L-index

#	Paper	IF	Citations
100	Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. <i>Journal of Biomedical Science</i> , 2021 , 28, 70	13.3	2
99	Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 112	7.3	2
98	Amelioration of lipopolysaccharide-induced memory impairment in equilibrative nucleoside transporter-2 knockout mice is accompanied by the changes in glutamatergic pathways. <i>Brain, Behavior, and Immunity</i> , 2021 , 96, 187-199	16.6	1
97	A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.. <i>Movement Disorders</i> , 2021 ,	7	2
96	Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells. <i>Molecular Neurobiology</i> , 2020 , 57, 1688-1703	6.2	1
95	Deletion of equilibrative nucleoside transporter-2 protects against lipopolysaccharide-induced neuroinflammation and blood-brain barrier dysfunction in mice. <i>Brain, Behavior, and Immunity</i> , 2020 , 84, 59-71	16.6	9
94	Enhanced Na ⁺ -K ⁺ -2Cl ⁻ cotransporter 1 underlies motor dysfunction in huntington's disease. <i>Movement Disorders</i> , 2019 , 34, 845-857	7	6
93	Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease. <i>Nature Communications</i> , 2019 , 10, 3473	17.4	78
92	Novel Adenosine Analog, 6-(4-Hydroxybenzyl)-Adenosine, Dampens Alcohol Drinking and Seeking Behaviors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 371, 260-267	4.7	7
91	Trax: A versatile signaling protein plays key roles in synaptic plasticity and DNA repair. <i>Neurobiology of Learning and Memory</i> , 2019 , 159, 46-51	3.1	2
90	Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment. <i>Journal of Neuroscience</i> , 2019 , 39, 1505-1524	6.6	11
89	Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018 , 55, 8936-8952	6.2	32
88	GSK3 β negatively regulates TRAX, a scaffold protein implicated in mental disorders, for NHEJ-mediated DNA repair in neurons. <i>Molecular Psychiatry</i> , 2018 , 23, 2375-2390	15.1	20
87	The adenosine A receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease. <i>Neurobiology of Disease</i> , 2018 , 110, 1-11	7.5	16
86	Beneficial Effect of a Selective Adenosine A Receptor Antagonist in the APP ^{swE} /PS1 ^{dE9} Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018 , 11, 235	6.1	45
85	Microglial Lectins in Health and Neurological Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2018 , 11, 158	6.1	19
84	Targeting ENT1 and adenosine tone for the treatment of Huntington's disease. <i>Human Molecular Genetics</i> , 2017 , 26, 467-478	5.6	23

83	Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease. <i>Movement Disorders</i> , 2017 , 32, 1600-1609	7	7
82	Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2017 , 11, 126	6.1	8
81	A central role of TRAX in the ATM-mediated DNA repair. <i>Oncogene</i> , 2016 , 35, 1657-70	9.2	14
80	Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. <i>Neurobiology of Disease</i> , 2016 , 96, 47-53	7.5	15
79	Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016 , 36, 1412-23	7.3	10
78	Type VI adenylyl cyclase negatively regulates GluN2B-mediated LTD and spatial reversal learning. <i>Scientific Reports</i> , 2016 , 6, 22529	4.9	4
77	Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by <i>supt4h</i> knockdown. <i>PLoS Genetics</i> , 2015 , 11, e1005043	6	36
76	AMPK-mediated regulation of neuronal metabolism and function in brain diseases. <i>Journal of Neurogenetics</i> , 2015 , 29, 50-8	1.6	38
75	Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism. <i>Autophagy</i> , 2015 , 11, 685-700	10.2	95
74	Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs. <i>Human Molecular Genetics</i> , 2015 , 24, 6066-79	5.6	45
73	Activation of AMP-activated protein kinase α mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2015 , 24, 787-801	5.6	45
72	Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. <i>Scientific Reports</i> , 2015 , 5, 14992	4.9	20
71	Aberrant astrocytes impair vascular reactivity in Huntington disease. <i>Annals of Neurology</i> , 2015 , 78, 178-92	9.4	54
70	Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. <i>Human Molecular Genetics</i> , 2015 , 24, 1602-16	5.6	52
69	Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. <i>FEBS Letters</i> , 2015 , 589, 432-9	3.8	29
68	High Protein Diet and Huntington's Disease. <i>PLoS ONE</i> , 2015 , 10, e0127654	3.7	8
67	The A2A adenosine receptor is a dual coding gene: a novel mechanism of gene usage and signal transduction. <i>Journal of Biological Chemistry</i> , 2014 , 289, 1257-70	5.4	25
66	AMPK- α functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 1668-80	6.9	49

65	Adenosine receptor neurobiology: overview. <i>International Review of Neurobiology</i> , 2014 , 119, 1-49	4.4	81
64	Adenosine receptors and Huntington's disease. <i>International Review of Neurobiology</i> , 2014 , 119, 195-232	4.4	28
63	Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. <i>Human Molecular Genetics</i> , 2014 , 23, 4328-44	5.6	69
62	Adenosine A(2A) receptor up-regulates retinal wave frequency via starburst amacrine cells in the developing rat retina. <i>PLoS ONE</i> , 2014 , 9, e95090	3.7	16
61	The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity. <i>PLoS ONE</i> , 2014 , 9, e103644	3.7	26
60	Lack of type VI adenylyl cyclase (AC6) leads to abnormal sympathetic tone in neonatal mice. <i>Experimental Neurology</i> , 2013 , 248, 10-5	5.7	2
59	A novel G β -binding protein, Gas-2 like 2, facilitates the signaling of the A2A adenosine receptor. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013 , 1833, 3145-3154	4.9	7
58	Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies. <i>Journal of Biomedical Science</i> , 2013 , 20, 47	13.3	18
57	Neurovascular abnormalities in humans and mice with Huntington's disease. <i>Experimental Neurology</i> , 2013 , 250, 20-30	5.7	59
56	A critical role of astrocyte-mediated nuclear factor- κ B-dependent inflammation in Huntington's disease. <i>Human Molecular Genetics</i> , 2013 , 22, 1826-42	5.6	147
55	Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 742-53	6.9	23
54	Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. <i>Molecular and Cellular Biology</i> , 2013 , 33, 1073-84	4.8	51
53	PPAR γ rescue of the mitochondrial dysfunction in Huntington's disease. <i>Neurobiology of Disease</i> , 2012 , 45, 322-8	7.5	70
52	Spt4 is selectively required for transcription of extended trinucleotide repeats. <i>Cell</i> , 2012 , 148, 690-701	56.2	73
51	Energy dysfunction in Huntington's disease: insights from PGC-1 α , AMPK, and CKB. <i>Cellular and Molecular Life Sciences</i> , 2012 , 69, 4107-20	10.3	25
50	A new drug design targeting the adenosinergic system for Huntington's disease. <i>PLoS ONE</i> , 2011 , 6, e20934	3.4	67
49	Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. <i>Handbook of Experimental Pharmacology</i> , 2011 , 267-310	3.2	58
48	Nuclear translocation of AMPK- α 1 potentiates striatal neurodegeneration in Huntington's disease. <i>Journal of Cell Biology</i> , 2011 , 194, 209-27	7.3	149

47	The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011 , 1812, 1111-20	6.9	31
46	Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1519-23	15.9	32
45	Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. <i>PLoS ONE</i> , 2011 , 6, e22924	3.7	77
44	Dendritic trafficking of brain-derived neurotrophic factor mRNA: regulation by translin-dependent and -independent mechanisms. <i>Journal of Neurochemistry</i> , 2011 , 116, 1112-21	6	34
43	Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. <i>ChemMedChem</i> , 2011 , 6, 1390-400	3.7	20
42	Type VI adenylyl cyclase regulates neurite extension by binding to Snapin and Snap25. <i>Molecular and Cellular Biology</i> , 2011 , 31, 4874-86	4.8	19
41	Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. <i>Human Molecular Genetics</i> , 2010 , 19, 4043-58	5.6	71
40	Supraspinal contribution to splanchnic sympathetic activity in neonatal mouse and rat brainstem-spinal cord in vitro. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2010 , 156, 51-9	2.4	5
39	Targeting glial cells to elucidate the pathogenesis of Huntington's disease. <i>Molecular Neurobiology</i> , 2010 , 41, 248-55	6.2	44
38	Impaired water reabsorption in mice deficient in the type VI adenylyl cyclase (AC6). <i>FEBS Letters</i> , 2010 , 584, 2883-90	3.8	26
37	The A2A adenosine receptor rescues neurogenesis impaired by p53 blockage via KIF2A, a kinesin family member. <i>Developmental Neurobiology</i> , 2010 , 70, 604-21	3.2	19
36	Longitudinal evaluation of an N-ethyl-N-nitrosourea-created murine model with normal pressure hydrocephalus. <i>PLoS ONE</i> , 2009 , 4, e7868	3.7	11
35	The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. <i>Human Molecular Genetics</i> , 2009 , 18, 2929-42	5.6	68
34	Novel regulation of adenylyl cyclases by direct protein-protein interactions: insights from snapin and ric8a. <i>NeuroSignals</i> , 2009 , 17, 169-80	1.9	21
33	Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. <i>Journal of Neuroscience</i> , 2008 , 28, 3277-90	6.6	91
32	Neuroprotective principles from <i>Gastrodia elata</i> . <i>Journal of Natural Products</i> , 2007 , 70, 571-4	4.9	67
31	Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. <i>Human Molecular Genetics</i> , 2007 , 16, 483-98	5.6	73
30	Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach. <i>Molecular and Cellular Proteomics</i> , 2007 , 6, 781-97	7.6	27

29	Regulation of type V adenylate cyclase by Ric8a, a guanine nucleotide exchange factor. <i>Biochemical Journal</i> , 2007 , 406, 383-8	3.8	24
28	Aspects of the general biology of adenosine A2A signaling. <i>Progress in Neurobiology</i> , 2007 , 83, 263-76	10.9	146
27	Rescue of p53 blockage by the A(2A) adenosine receptor via a novel interacting protein, translin-associated protein X. <i>Molecular Pharmacology</i> , 2006 , 70, 454-66	4.3	50
26	CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. <i>Journal of Neurochemistry</i> , 2005 , 93, 310-20	6	145
25	cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. <i>Journal of Biological Chemistry</i> , 2005 , 280, 14331-40	5.4	75
24	An important functional role of the N terminus domain of type VI adenylyl cyclase in Galphai-mediated inhibition. <i>Journal of Biological Chemistry</i> , 2004 , 279, 34440-8	5.4	10
23	Regulation of type VI adenylyl cyclase by Snapin, a SNAP25-binding protein. <i>Journal of Biological Chemistry</i> , 2004 , 279, 46271-9	5.4	37
22	Characterization of the rat A2A adenosine receptor gene: a 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. <i>European Journal of Neuroscience</i> , 2003 , 18, 1786-96	3.5	51
21	Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A(2A) adenosine receptor. <i>Molecular Brain Research</i> , 2003 , 111, 61-73		14
20	Essential role of cAMP-response element-binding protein activation by A2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. <i>Journal of Biological Chemistry</i> , 2002 , 277, 33930-42	5.4	76
19	Protein kinase C inhibits type VI adenylyl cyclase by phosphorylating the regulatory N domain and two catalytic C1 and C2 domains. <i>Journal of Biological Chemistry</i> , 2002 , 277, 15721-8	5.4	32
18	N-glycosylation and residues Asn805 and Asn890 are involved in the functional properties of type VI adenylyl cyclase. <i>Journal of Biological Chemistry</i> , 2001 , 276, 35450-7	5.4	28
17	Activation of protein kinase A and atypical protein kinase C by A(2A) adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. <i>Journal of Biological Chemistry</i> , 2001 , 276, 13838-46	5.4	78
16	Regulation of adenylyl cyclase in the central nervous system. <i>Cellular Signalling</i> , 2000 , 12, 195-204	4.9	71
15	Modulation of dopamine transporter activity by nicotinic acetylcholine receptors and membrane depolarization in rat pheochromocytoma PC12 cells. <i>Journal of Neurochemistry</i> , 1999 , 72, 2437-44	6	18
14	The 5' untranslated regions of the rat A2A adenosine receptor gene function as negative translational regulators. <i>Journal of Neurochemistry</i> , 1999 , 73, 1790-8	6	22
13	The N terminus domain of type VI adenylyl cyclase mediates its inhibition by protein kinase C. <i>Molecular Pharmacology</i> , 1999 , 56, 644-50	4.3	46
12	Expression of type VI adenylyl cyclase in the central nervous system: implication for a potential regulator of multiple signals in different neurotransmitter systems. <i>FEBS Letters</i> , 1998 , 436, 92-8	3.8	32

11	Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response. <i>Journal of Biological Chemistry</i> , 1997 , 272, 4970-7	5.4	95
10	Circadian rhythm in the Ca(2+)-inhibitable adenylyl activity of the rat striatum. <i>FEBS Letters</i> , 1996 , 385, 205-8	3.8	9
9	Insulin-dependent translocation of the small GTP-binding protein rab3C in cardiac muscle: studies on insulin-resistant Zucker rats. <i>FEBS Letters</i> , 1995 , 377, 109-12	3.8	7
8	Distribution and regulation of rab3C, a small molecular weight GTP-binding protein. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 200, 1257-63	3.4	12
7	Molecular cloning of a novel adenosine receptor gene from rat brain. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 185, 304-9	3.4	63
6	The adenosine analogue N6-L-phenylisopropyladenosine inhibits catecholamine secretion from bovine adrenal medulla cells by inhibiting calcium influx. <i>Journal of Neurochemistry</i> , 1992 , 59, 1399-404	6	9
5	Presence of Na ⁺ /Ca ²⁺ exchange activity and its role in regulation of intracellular calcium concentration in bovine adrenal chromaffin cells. <i>Cell Calcium</i> , 1992 , 13, 99-106	4	27
4	Structural role of amino acids 99-110 in recombinant human erythropoietin. <i>FEBS Journal</i> , 1991 , 202, 225-9		16
3	Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 2535-9	11.5	7
2	Adenosine receptors activate adenylate cyclase and enhance secretion from bovine adrenal chromaffin cells in the presence of forskolin. <i>Journal of Neurochemistry</i> , 1988 , 50, 1484-93	6	41
1	Inhibition of catecholamine secretion from bovine chromaffin cells by adenine nucleotides and adenosine. <i>Journal of Neurochemistry</i> , 1987 , 48, 1573-6	6	42